Fate Therapeutics Q3 EPS $(0.25) Beats $(0.27) Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 7.41 percent increase over losses of $(0.27) per share from
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 7.41 percent increase over losses of $(0.27) per share from the same period last year.